Alirocumab Alternatives Compared
| Alirocumab | Repatha (evolocumab) | Atorvastatin |
|
|---|
| Alirocumab | Repatha (evolocumab) | Atorvastatin |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for High Cholesterol - Familial Homozygous, Cardiovascular Risk Reduction, High Cholesterol, High Cholesterol - Familial Heterozygous. Alirocumab may also be used for purposes not listed... View more |
Prescription only
Repatha is a PCSK9 inhibitor that may be used to reduce LDL-C levels in people with primary hyperlipidemia and HoFH, and also to reduce the risk of cardiovascular events in adults with established... View more |
Prescription only
Atorvastatin is effective at lowering cholesterol; however, its use may be limited by side effects such as muscle pain. Prescribed for High Cholesterol, High Cholesterol - Familial Homozygous, High... View more |
Related suggestions High Cholesterol
High Cholesterol, Familial Heterozygous
High Cholesterol, Familial Homozygous
|
|||||||||||||||
| More about Alirocumab | More about Repatha (evolocumab) | More about Atorvastatin | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Alirocumab has an average rating of 6.2 out of 10 from a total of 313 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 31% reported a negative effect. |
Repatha has an average rating of 5.3 out of 10 from a total of 685 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 46% reported a negative effect. |
Atorvastatin has an average rating of 4.3 out of 10 from a total of 298 ratings on Drugs.com. 28% of reviewers reported a positive effect, while 54% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Alirocumab side effects |
View all Repatha side effects |
View all Atorvastatin side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Repatha prices |
View all Atorvastatin prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Praluent |
N/A |
Atorvaliq, Lipitor | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
480 hours |
408 hours |
14 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 2 drugs are known to interact with Alirocumab:
|
A total of 2 drugs are known to interact with Repatha:
|
A total of 402 drugs are known to interact with Atorvastatin:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||
| Disease Interactions | ||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
July 24, 2015 |
August 27, 2015 |
December 17, 1996 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
|
||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.